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Acute liver failure (ALF) affects approximately 2000 persons annually in the United States
1
 and 
is caused by acetaminophen toxicity in about half of the cases.
2
 Acute kidney injury (AKI) 
develops in 75% of cases caused by acetaminophen toxicity and much less with other 
etiologies.
3,4
 Cerebral edema (CE) is one of the most common complications, and occurs in up to 
80% of patients with severe encephalopathy.
1
 Without liver transplantation, the mortality rate is 
around 30% usually in the setting of infection and CE.
1,4-7
 The etiology of CE is multifactorial 
and not fully understood. It might result from increased brain water content induced by the 
accumulation of osmotically active glutamine derived from ammonia in the astrocytes.
8
 Rapid 
dialytic removal of urea and other uremic solutes might also induce or exacerbate CE.
9-11
 Several 
strategies have been implemented to prevent and treat CE, with induction of systemic plasma 
hypertonicity using hypertonic saline or mannitol therapy being the cornerstone of management. 
In patients suffering from concomitant kidney injury, plasma hypertonicity can be regulated by 
adjusting the prescription of continuous renal replacement therapy (CRRT) to achieve and 
maintain a specific higher systemic sodium level ([Na]Sys). Herein, we describe our experience 
regulating plasma hypertonicity in ALF using a high-sodium online-generated dialysate with 24-




Since the implementation of our near-automated ol-CVVHD-RCA program at Henry 
Ford Hospital
12,13
 starting in 2009, we used it to regulate plasma hypertonicity in most patients 
with ALF, CE, and AKI requiring CRRT. Table 1 summarizes the demographics and clinical 
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settings of eleven consecutive patients who presented between January 2011 and July 2013. Our 
patients were severely ill with an elevated predicted mortality rate thus ol-CVVHD-RCA was 
our CRRT modality of first choice. Following an institutional protocol, five patients had an intra-
cranial pressure (ICP) monitor inserted after receiving hypertonic saline at the first clinical or 




 we used a Fresenius 2008K or K2 (Fresenius Medical Care, 
North America, Waltham, MA) machine in pediatric intermittent hemodialysis (IHD) mode to 
deliver a blood flow (QB) of 60 ml/min and a dialysate flow (QD) of 400 ml/min. CRRT is 
achieved by running 9-hour 59-minute IHD sessions separated by a 20-second machine reset 
procedure. Vascular access was established through central venous hemodialysis catheters. We 
used the high-flux and high-efficiency Rexeed 15S hemodialyzer (Asahi-Kasei Corp., Tokyo, 
Japan) which delivers a substantial dose of internal hemofiltration-backfiltration due to its very 
high ultrafiltration coefficient. The delivered net ultrafiltration rate ranged from zero to 200 
ml/hour (possible 0-500 protocol range), based on individual settings. Online prescription 
(selection from the machine screen menu) was used to generate a dialysis fluid with a fixed 
sodium level up to 155 mEq/L (range 130-155). The conductivity of the fresh dialysate was 
monitored and is a surrogate for the final dialysate sodium concentration. Our 24-hour ol-
CVVHD-RCA therapy delivers about 3 liters of urea clearance and sodium dialysance per hour 
and therefore was not expected to provide a rapid, immediate increase in [Na]Sys. Since CE is a 
medical emergency that necessitates immediate intervention, all patients initially received either 
23.4% saline as intravenous boluses (“saline bullets”) or a continuous infusion of 3% saline 
through a central venous catheter. This maneuver provided the desired acute rise in [Na]Sys and 
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plasma tonicity, with ol-CVVHD-RCA then used to maintain the [Na]Sys within the target range. 
Weaning of plasma hypertonicity was dictated by radiologic and clinical signs of resolution of 
CE. Owing to the availability of highly reliable conductivity sensor technology standard on all 
modern hemodialysis machines, we measured the effective ionic dialysance (Kecn)
14
 during 
CRRT every 100 minutes and used it to quantify the volume of systemic blood equilibrating with 
the fresh dialysate sodium level ([Na]Din) while accounting for the variation in plasma protein 
level, red blood cell permeability, and Donnan factor expected to occur in a critically ill patient. 
Figure (1) details our sodium kinetic modeling, where equation (3) was used to predict the 
[Na]Sys.
15
 Sodium and potassium total content and total body water volume changes derived from 
the gain or loss of fluids non-isotonic to [Na]Din were included in the calculations and 
represented by the artificial kinetic term, sodium generation per hour, G averaged over a 24-hour 
period. This was done to account for the non-negligible effect on [Na]Sys of continuous dilute IV 
fluids (e.g. catecholamines or N-acetylcysteine in 5% dextrose-water) often needed in the care of 
ALF patients. Sodium lost with gastric secretions and stool was practically difficult to account 
for and was ignored. Urine output was negligible. For mathematical simplicity we used single-
pool fixed-volume sodium kinetic modeling
16
 thus we did not account for the changes in total 
body water (TBW) induced by fluid administration or body fluid losses naturally or through 
ultrafiltration. Finally, the pre-filter use of hypernatremic citrate infusion did not affect the return 
blood sodium level or the [Na]Sys as the protocol ensured that the circuit blood sodium was fully 
equilibrated to the fresh dialysate fluid sodium level. Systemic citrate accumulation was avoided 
even in the assumed absence of liver metabolism of citrate as all the infused citrate (>95%) was 
dialyzed out in a single pass and hence never entered the systemic circulation. 
The time, t in hours required to achieve the desired [Na]Sys target was estimated 
predominantly from an equation using the prescriber set difference between the systemic sodium 
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level and the fresh dialysate sodium level at start of the CRRT modeling period ([Na]Sys(0h) - 
[Na]Din), multiplied by the exponential term -Deff * t/V = -Kecn * t/TBW (Figure 1). As we did not 
expect multi-compartment sodium kinetics during our low efficiency continuous dialysis 
modality,
16
 the single-pool fixed-volume sodium kinetic modeling equation was used: 
[Na]Sys(t) = [Na]Din +  ([Na]Sys(0h) - [Na]Din) * e
-Kecn*t/TBW
 + G/Kecn * (1- e
-Kecn*t/TBW
) 
where the effective sodium dialysance Deff (L/hour) is replaced by the about equal effective ionic 
dialysance Kecn (L/hour) which in turn is very accurately and automatically measured by the 
dialysis machine about every 2 hours during CRRT. The Kecn is about equal to Keff which 
represents the effective urea clearance and allows us to express the delivered CRRT dose in 
terms of estimated standard urea Kt/V. A standard urea Kt/V of 1.2 is about equivalent to 30 
ml/kg/hour of post-dilution equivalent continuous urea clearance. The t is the time needed to 
achieve the desired [Na]sys in hours, V the apparent volume of distribution of sodium in L and 
can be replaced by an estimate of the total body water (TBW). The calculation of the artificial 
kinetic term G in mEq/hour is only needed if the patient is experiencing large fluid gains or 
losses non-isotonic to the fresh dialysate and can be ignored otherwise. During the ol-CVVHD-
RCA with QB of 60 mL/min, we recorded around one-thousand K readings with a mean ± 
standard error of 55.44 ± 0.1 ml/mn. Assuming a patient with TBW of 45 L and [Na]Sys(0h) of 140 
mEq/L without the use of HS, a desired goal serum sodium of 153 mEq/L at 24-hour into ol-
CVVHD-RCA ([Na]Sys(24h)) and fresh [Na]Din of 155 mEq/L, the NaRR (or the reduction of the 
sodium difference between systemic sodium at start of the ol-CVVHD-RCA session and the 
fresh dialysate sodium) will be equal to 0.86, derived from: ([Na]Sys(24h) - [Na]Sys(0h))/([Na]Sys(0h) - 
[Na]Din). When using the equation above, t required to reach steady state with [Na]Sys = [Na]Din 
will be about 27 hours. These kinetic predictions explain our clinical practice of using hypertonic 
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saline initially to acutely raise the [Na]Sys concentration followed by the ol-CVVHD-RCA 
mostly to maintain the goal [Na]Sys. During modeling we ignored the effect of net ultrafiltration 
(fixed volume kinetic model) as it was expected to be isotonic to the [Na]Din and hence not 
impact the [Na]Sys significantly. We also did not calculate the difference between the laboratory 
reported serum sodium level and the blood water sodium concentration nor the impact of the 
Donnan factor on sodium fluxes on the dialyzer (fortuitously the effects of these latter 
simplifications essentially cancel out each other). The resulting fixed volume, single-pool 
sodium dialysance equation is simple enough for routine clinical use and appears to be clinically 
sufficiently accurate during the conditions of ol-CVVHD-RCA. 
Results 
 The duration of high sodium ol-CVVHD-RCA treatment ranged from 4 to 13 days. 
Within 24 hours of start, all patients had their sodium levels at or around the specified target. 
Severe hypernatremia or unexpected changes in [Na]Sys did not occur in any patient. Similarly, 
the [Na]Sys was maintained throughout the duration of therapy, and was not significantly lowered 
despite the large loads of free water used to deliver antibiotics and/or continuous infusions of 
pressors and antidotes such as N-acetylcysteine in hypotonic IV fluids. Figure 2 provides details 
regarding the actual [Na]Sys, the [Na]Sys goal, and the prescribed fresh dialysate sodium 
concentration [Na]Din. Using the ol-CVVHD-RCA approach, we did not encounter any 
complication related to citrate accumulation or toxicity such as ionized hypocalcemia or 
abnormally high total-to-ionized calcium ratio. One hundred and sixty serum ionized calcium 
levels out of 162 were within normal laboratory reference of 1-1.3 mmol/L. Two values of 0.91 
mmol/L and 1.33 mmol/L were of no clinical significance. For patients who had an ICP monitor, 
we did not observe any increase in the ICP at the start or throughout the ol-CVVHD-RCA 
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therapy, including patients who received this treatment the longest (Table 2). The modality- 
related downtime was 53.5 hours of 1902 prescribed hours, accounting for 2.81%. The patient 
suffering from Budd-Chiari syndrome as well as one patient with acetaminophen toxicity died 
despite maintaining target [Na]Sys levels. Among the nine patients who survived, none required 
liver transplantation. Seven patients had normalization of their serum creatinine and liver 
function tests, while the remaining two had partial improvement in both organ functions and 
were discharged without requiring outpatient dialysis and were lost to follow-up. 
DISCUSSION 
             The regeneration of hepatocytes in patients surviving ALF starts after 3 days
17
 with 
restoration of liver function occurring within 10 days.
18
 Optimal organ support is crucial within 
this 10-day window while awaiting liver recovery, especially managing any concomitant AKI 
and CE. Frequently used agents such as mannitol and hypertonic saline are associated with 
various adverse events, including volume expansion and rebound cerebral edema especially 
during sudden withdrawal without prior weaning.
19-25
 In this paper, we assume that osmotherapy 
delivered through the modification of the replacement/dialysate fluid sodium level offers 
numerous advantages over the conventional methods. The desired [Na]Sys can be smoothly 
maintained with less risk of hypernatremia, and gradually reversed at the end of therapy with less 
risk for rebound cerebral edema. In addition, the volume overload and the metabolic disturbances 
resulting from the renal failure itself or from the induced hypernatremia, such as metabolic 
acidosis, hypokalemia, or hyperkalemia, can be easily addressed and managed. The use of a 
modified dialysate sodium concentration has been previously reported for the management of 
dysnatremias.
26-28
 In a 5 L bag, the sodium concentration can be raised from 140 mEq/L to 154 
mEq/L by the addition of 17.5 mL of 23.4% hypertonic saline (sodium concentration of 4 
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mEq/mL). This approach has three major drawbacks: significant financial cost of CVVH 
compared to the much less expensive ol-CVVHD-RCA, an additional workload imposed on the 
pharmacy personnel who perform the mixing, and the risk of contamination and errors during the 
injection of HS into the fluid bags. The last concern is highly significant as fatal errors during the 
compounding of replacement fluid bags have been reported.
29
 For these reasons, many hospital 
pharmacies prohibit the modifications of CRRT fluid bags. Moreover, the weaning phase of 
hypernatremia when the target serum sodium [Na]Sys is gradually decreased might be difficult 
with the need for repetitive calculations. All of these represent possibilities for additional error 
and wasting of incompletely utilized fluid bags. This ol-CVVHD-RCA protocol offers numerous 
advantages over conventional continuous RRT (CRRT), including much less cost, simpler 
logistics of therapy delivery, and less risk of dosing errors. This method warrants less frequent 
laboratory testing given the general stability of the [Na]Sys, and helps the intensive care team 
focus on addressing some of the other complex issues. The weaning phase of hypernatremia 
specifically proved smoother, with the target sodium and bicarbonate in the fresh dialysate 
adjusted as needed through simply pressing a few buttons on the machine screen. It is important 
to emphasize that citrate should not be used in patients with ALF unless the single pass dialyzer 
removal of citrate exceeds at least 80% (95-98% in the current protocol). In addition, the dialysis 
modality used should have the least possible downtime to avoid dangerous fluctuations in the 
serum sodium levels. A key feature of our model is the ability to measure Kecn repeatedly and 
provide feedback about vascular access and dialyzer performances in delivering the prescribed 
sodium dialysance. This is a crucial safety measure that eliminates the risk of fluctuations in 
serum sodium level or life-threatening citrate accumulation and toxicity in our vulnerable 
patients with ALF. Additionally, the precise delivery of hypernatremic therapy with this model 
requires strict quality control of every step of dialysate generation, which starts with the acid- 
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and bicarbonate concentrate mixing process (performed by two trained technicians working 
together) and ends with the final proportioning on the dialysis machine. Dialysis technicians 
were available on-site 24/7 to answer any conductivity alarms. 
CRRT in general might be the preferred method for delivering both renal replacement 
therapy and high plasma tonicity control in patients with ALF, owing to the common occurrence 
of circulatory dysfunction resulting in fragile hemodynamics. If intermittent hemodialysis or 
higher intensity hemofiltration (shift-therapy) are used for the management of the co-existing 
renal failure, they may worsen the intra-cranial hypertension through the dialysis disequilibrium 
phenomenon, and through the induction of hypotension, which leads to a decrease in the cerebral 
perfusion pressure and a reflex cerebral vasodilation, thereby raising the ICP.
30,31
 These changes 
may occur within the first hour of treatment, before any major changes in plasma osmolality 
have occurred. Despite CRRT being reported to avoid this problem,
32,33
 an increase in ICP as 
early as 3 hours after initiation of CVVH and SLED has been reported.
34
 The absence of such 
findings in our patients might be owing to the extremely low blood flow (60 ml/mn) and sodium 
dialysance or urea clearance of <=55 ml/ min.  
CONCLUSION 
The use of high sodium ol-CVVHD-RCA in general might be superior to the conventional 
approach in the management of cerebral edema in the context of ALI and AKI. Our model in 
particular is an effective, simple, and safe alternative for maintaining and weaning a high target 
[Na]Sys. Although it offers many advantages over conventional therapies, our data cannot 
advocate the use of hypernatemia in patients with CE but rather provides a reliable method of 
delivery if this approach is to be pursued. This model is expected to be further studied and small 
improvements to be made with more experience. Finally, more data is needed to clarify whether 
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this proposed model will provide any morbidity or mortality benefit beside optimizing and 
simplifying the treatment of cerebral edema in the described settings.  
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1 43, F Septic 
shock 
17 39 Normal Yes  No No 
2 50, F Budd-
Chiari 
10 45 Normal No No No 
3 24, F APAP 14 23 unknown Yes No No 
4 40, F APAP 16 35 Normal Yes Yes Yes 
5 34, F APAP 16 33 Normal Yes Yes Yes 
6 42, F APAP 14 42 Normal Yes No No 
7 25, M APAP 14 45 unknown Yes No No 
8 19, F APAP 11 51 unknown No No No 
9 36, F APAP 14 36 Normal Yes Yes Yes 
10 54, F APAP 13 37 Normal Yes Yes Yes 
11 44, F unknown 9 29 Normal Yes Yes Yes 
ALI: acute liver in injury; APAP: N-acetyl-para-aminophenol; SOFA: sequential organ failure 
assessment. Initial score of more than 11 is associated with a mortality rate >90%, while a score 
of 8-11 is associated with a mortality rate of 60%; MELD: model for end-stage liver disease 
score at time of initiation of ol-CVVHD-RCA; MV: mechanical ventilation; ICP: intra-cranial 
pressure. Patients 2 and 5 did not survive. 
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Table 2. Intra-cranial pressure values before and during ol-CVVHD-RCA 
Case 
No 
At insertion of 
ICP monitor 
At initiation of ol-
CVVHD-RCA 
6 hrs 1 d 2 d 3 d 4 d 5 d 6 d 7 d 
4 18 18 15 10 6 8 7 9 7  
5 19 5 13 5 95 111        
9 17 5 9 8 2 3 4 4 9 6 
10 22 10 19 12 18 14       
11 17 19 19 5 8 2 2    
Intra-cranial pressure (ICP) values in mmHg of five patients who had an ICP monitor insertion. 
Data represents ICP at the time of insertion of the ICP monitor, at the initiation of ol-CVVHD-
RCA, after 6 hours, and up to 7 days. All patients received hypertonic saline before the insertion 
of the ICP monitor due to radiographic signs of cerebral edema and at initiation of ol-CVVHD-
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Figure 1. Sodium fluxes across the dialyzer. 
Figure (1).Top: sodium fluxes across the dialyzer. Due to complete equilibrium with the 
dialysate [Na]out = [Na]Din. Any infusion or fluid loss which is not isotonic to [Na]Din will 
contribute to the arbitrary kinetic construct “sodium generation” G (mEq/h) as defined in the 
figure; net ultrafiltrate is isotonic and thus is ignored. If all gain and loss of fluid is isotonic to 
[Na]Din then G will be zero. QBe effective blood flow for sodium (blood water flow), QD 
dialysate flow, QUF ultrafiltration flow. All flow rates in L/hr. [Na]in,out sodium concentration 
(mEq/L) at the dialyzer blood inlet and outlet, respectively. [Na]Din,Dout sodium concentration 
(mEq/L) at the dialyzer dialysate inlet and outlet, respectively. Nain,out amount of sodium 
(mEq/24hr) gained or lost, respectively. Kin,out amount of potassium (mEq/24hr) gained or lost, 
respectively. Vin,out volume of water (L/24hr) gained through infusion or lost through drainage or 
loss of body fluids, respectively. R: access recirculation. Bottom: sodium kinetic equations. Eq. 
(1) derives the Keff (effective urea clearance in L/h) after correcting dialyzer urea clearance (K, in 
L/hr) for access recirculation. In our venous-venous access model there is no cardiopulmonary 
recirculation. Therefore, as Eq. (2) shows Keff can be measured by the Kecn: effective 
conductivity clearance (L/h) which in turn is near equal to D (effective sodium dialysance in 
L/h). Eq. (3) calculates the TBW(t) (total body water in L at time t) which is equal to the initial 
TBW(0h)  derived from the EEW (estimated euvolemic weight in Kg) using the Watson’s formula 
in addition to any weight gain which is considered 100% water. The latter is the difference 
between the DW(t)  (daily weight at time t in Kg) and EEW. Finally, we derive Eq. (4) to predict 
the patient’s systemic sodium concentration. [Na]Sys(t) the systemic sodium concentration at time 
t (mEq/L). [Na]Sys(0h) the systemic sodium concentration at initiation of dialysis, t: time on 
dialysis (hr). To avoid a more complex kinetic equation we assume that TBW is fixed, still 
achieving clinically acceptable accuracy. We also assume that the correction factor applied when 
reporting serum Na concentrations from the clinical laboratory and the Donnan-factor on the 
dialyzer cancel each other out and therefore can be omitted. 
Figure 2.  Individual serum, dialysis fluid, and target sodium levels. 
 X-axis indicates time in days and Y-axis denotes serum sodium concentration (mEq/L). Filled 
diamonds (♦) and broken (- - -) lines indicate achieved serum sodium levels and dialysate sodium 
concentrations, respectively. Solid arrows indicate administration of 20 ml of 23.4% saline bolus. 
Shaded areas indicate desired serum sodium concentration range. Note that identical serum 
sodium values throughout a day are superimposed. The decrease in the dialysate sodium 
indicates the weaning from osmotherapy and the disappearance of the broken line indicated the 
stopping of CVVHD-RCA. Patients (2) and (5) died. Patients (5) and (8) depicted in the right 
lower corner underwent the shortest duration of therapy. * sodium level likely a laboratory error; 
rechecked immediately and was 150 mEq/L. 
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